BMO Capital Markets set a $64.00 price target on Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research analysts have also recently issued reports on ONCE. Mizuho reaffirmed a buy rating and issued a $79.00 price target on shares of Spark Therapeutics in a report on Wednesday. Stifel Nicolaus reaffirmed a buy rating and issued a $64.00 price target (down from $73.00) on shares of Spark Therapeutics in a report on Wednesday. Sanford C. Bernstein reaffirmed a buy rating and issued a $60.00 price target (down from $71.00) on shares of Spark Therapeutics in a report on Wednesday. They noted that the move was a valuation call. Royal Bank of Canada reaffirmed an outperform rating and issued a $65.00 price target on shares of Spark Therapeutics in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. cut Spark Therapeutics from an overweight rating to a neutral rating and cut their price target for the company from $62.00 to $60.00 in a report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $69.88.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $0.83 during trading hours on Wednesday, hitting $55.02. 568,577 shares of the stock traded hands, compared to its average volume of 608,482. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75. The firm has a market cap of $2,043.00, a P/E ratio of -7.12 and a beta of 3.02.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($1.73). Spark Therapeutics had a negative return on equity of 65.56% and a negative net margin of 2,100.80%. The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. analysts predict that Spark Therapeutics will post -3.77 EPS for the current year.
In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the completion of the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $15,333,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.30% of the company’s stock.
A number of large investors have recently made changes to their positions in ONCE. Ameritas Investment Partners Inc. raised its holdings in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Spark Therapeutics during the 2nd quarter worth about $143,000. Public Employees Retirement Association of Colorado bought a new stake in Spark Therapeutics during the 4th quarter worth about $163,000. Aperio Group LLC raised its holdings in Spark Therapeutics by 29.2% during the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 898 shares during the last quarter. Finally, Xact Kapitalforvaltning AB bought a new stake in Spark Therapeutics during the 4th quarter worth about $208,000.
COPYRIGHT VIOLATION NOTICE: This report was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://transcriptdaily.com/2018/02/25/spark-therapeutics-once-given-a-64-00-price-target-by-bmo-capital-markets-analysts.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.